Abstract
As a calcineurin inhibitor, cyclosporine selectively acts on T lymphocytes. It has been approved to be used in the treatment of psoriasis by the U.S. Food and Drug Administration since 1997. Also, it could be applied to treat some other immune-mediated dermatoses, such as psoriatic arthritis, atopic dermatitis, pyoderma gangrenosum, blistering disorders, lichen planus, chronic idiopathic urticaria and connective tissue diseases. In the last decade, many dermatologists have hesitated to use it in their clinical practice because of its toxicity profile. However, cyclosporine has been proved to be safe and effective for the treatment of some immune-mediated dermatoses. The author summarizes the outcomes of and considerations in the treatment of immune-mediated dermatoses with cyclosporine, in hope to make dermatologists feel comfortable and safe incorporating cyclosporine into their prescribing regimens. Key words: Skin diseases; Immunity; Cyclosporine
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
